Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008
Noncompliance on antituberculosis treatment and the psychological profile Source: Eur Respir J 2001; 18: Suppl. 33, 467s Year: 2001
Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Response of pulmonary tuberculoma to anti-tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 521s Year: 2003
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Rapid oral desensitization to anti-tuberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Surgical treatment of first found pulmonary tuberculosis at ineffectiveness of DOTS therapy Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Long-term results of drug resistant tuberculosis treatment Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006